Utilidad de la detección de antígenos de helicobacter pylori en heces en el diagnóstico de infección y en el control de la erradicación tras el tratamiento

Romero Gómez, Manuel; Vargas, Julio; Grande, Lourdes; Otero, M Angeles; Bernal, Samuel; Castro Fernández, Manuel.
Med. clín (Ed. impr.) ; 114(15): 571-573, abr. 2000.
Artículo en Es | IBECS (España) | ID: ibc-6386

Documentos relacionados

  1. Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
  2. Rifabutin triple therapy increased <i>H pylori</i> eradication vs. amoxicillin + omeprazole in treatment-naive patients.
  3. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
  4. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
  5. Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia.
  6. Treating Helicobacter pylori infection in the face of growing antibiotic resistance.
  7. Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.
  8. Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial.
  9. Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.
  10. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.